Given that patients with dominant or secondary TET2 mutations were unlikely to have MDS/MPN, one could hypothesize that phenotypic penetrance of SRSF2 mutations would likely be greater than that of TET2 mutations. This evidence concerns the gene TET2 and myelodysplastic syndrome.